Stocksigma LogoStocksigma Logo

Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility

Alembic Pharmaceuticals received USFDA final approval on 30th Oct'26 for its ANDA for Venetoclax Tablets (10 mg, 50 mg, and 100 mg), generic to AbbVie's

Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility

Alembic Pharmaceuticals Ltd 路 Press Release 路 30 Oct 2026, 11:59 pm

Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility Alembic Pharmaceuticals received USFDA final approval on 30th Oct'26 for its ANDA for Venetoclax Tablets (10 mg, 50 mg, and 100 mg), generic to AbbVie's Venclexta. As a first-to-file Paragraph IV applicant, Alembic may be eligible for 180 days of generic exclusivity. The product addresses CLL, SLL, and AML indications, targeting an estimated US market size of US $1,584 million for the twelve months ending Jun'26. Alembic now holds a cumulative total of 248 USFDA ANDA approvals, comprising 228 final and 20 tentative approvals.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements